DK1309355T3 - Peptid og peptidmimetika-konjugater med integrin-inhibitor-egenskaber - Google Patents

Peptid og peptidmimetika-konjugater med integrin-inhibitor-egenskaber

Info

Publication number
DK1309355T3
DK1309355T3 DK01960612T DK01960612T DK1309355T3 DK 1309355 T3 DK1309355 T3 DK 1309355T3 DK 01960612 T DK01960612 T DK 01960612T DK 01960612 T DK01960612 T DK 01960612T DK 1309355 T3 DK1309355 T3 DK 1309355T3
Authority
DK
Denmark
Prior art keywords
lys
peptide
molecule
group
po3h2
Prior art date
Application number
DK01960612T
Other languages
English (en)
Inventor
Michel Dard
Guenter Hoelzemann
Horst Kessler
Joerg Meyer
Berthold Nies
Martin Kantlehner
Ulrich Hersel
Christoph Gibson
Gabor Sulyok
Original Assignee
Biomet Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomet Deutschland Gmbh filed Critical Biomet Deutschland Gmbh
Application granted granted Critical
Publication of DK1309355T3 publication Critical patent/DK1309355T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
DK01960612T 2000-08-17 2001-08-02 Peptid og peptidmimetika-konjugater med integrin-inhibitor-egenskaber DK1309355T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10040105A DE10040105A1 (de) 2000-08-17 2000-08-17 Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften
PCT/EP2001/008932 WO2002013872A1 (de) 2000-08-17 2001-08-02 Peptid- und peptidmimetikakonjugate mit integrin-inhibitor-eigenschaften

Publications (1)

Publication Number Publication Date
DK1309355T3 true DK1309355T3 (da) 2008-08-25

Family

ID=7652668

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01960612T DK1309355T3 (da) 2000-08-17 2001-08-02 Peptid og peptidmimetika-konjugater med integrin-inhibitor-egenskaber

Country Status (19)

Country Link
US (1) US7655624B2 (da)
EP (1) EP1309355B9 (da)
JP (1) JP4902090B2 (da)
KR (1) KR20030062319A (da)
CN (1) CN1447699A (da)
AT (1) ATE395085T1 (da)
AU (1) AU2001282059A1 (da)
CA (1) CA2419423C (da)
CY (1) CY1108898T1 (da)
CZ (1) CZ2003692A3 (da)
DE (2) DE10040105A1 (da)
DK (1) DK1309355T3 (da)
ES (1) ES2306723T3 (da)
HU (1) HUP0301396A2 (da)
MX (1) MXPA03001428A (da)
PL (1) PL358809A1 (da)
PT (1) PT1309355E (da)
WO (1) WO2002013872A1 (da)
ZA (1) ZA200302049B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10040105A1 (de) 2000-08-17 2002-02-28 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften
WO2002040073A1 (en) * 2000-11-20 2002-05-23 Université De Genève Endosseous implant
DE10325049A1 (de) * 2003-06-02 2004-12-23 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften III
ATE462451T1 (de) * 2004-06-16 2010-04-15 Affinergy Inc Grenzflächenbiomaterialien zur förderung der anhaftung von zielanalyten
US20090053280A1 (en) * 2007-05-15 2009-02-26 Michael Joner Coating stents with cyclic rgd peptides or mimetics
KR102017026B1 (ko) * 2013-01-10 2019-09-02 (주) 수파드엘릭사 염증 또는 알러지의 예방 또는 치료용 약학 조성물 및 염증 또는 알러지 개선용 화장료 조성물
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
BR112019012071A2 (pt) 2016-12-14 2019-11-12 Progenity Inc tratamento de uma doença do trato gastrointestinal com um inibidor de integrina
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4310643A1 (de) 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
ATE277645T1 (de) 1997-05-22 2004-10-15 Biomet Deutschland Gmbh Peptid-beschichtete implantate und verfahren zu ihrer herstellung
DE19755801A1 (de) 1997-12-16 2000-06-21 Merck Patent Gmbh Mit die Zelladhäsion vermittelnden Peptiden beschichtete Implantate und Verfahren zu ihrer Herstellung
DE19755800A1 (de) 1997-12-16 1999-06-17 Merck Patent Gmbh Cyclopeptidderivate
DE19831710A1 (de) 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
DE19932796A1 (de) 1999-07-14 2001-01-18 Merck Patent Gmbh Diacylhydrazinderivate
DE10040105A1 (de) 2000-08-17 2002-02-28 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften
US20070137128A1 (en) 2005-12-02 2007-06-21 Nicolas Viau Modular stone panel

Also Published As

Publication number Publication date
DE10040105A1 (de) 2002-02-28
ES2306723T3 (es) 2008-11-16
US7655624B2 (en) 2010-02-02
US20040029782A1 (en) 2004-02-12
JP4902090B2 (ja) 2012-03-21
MXPA03001428A (es) 2003-06-06
PT1309355E (pt) 2008-08-26
HUP0301396A2 (hu) 2003-09-29
KR20030062319A (ko) 2003-07-23
ATE395085T1 (de) 2008-05-15
EP1309355B1 (de) 2008-05-14
CZ2003692A3 (cs) 2003-06-18
ZA200302049B (en) 2004-08-27
CA2419423A1 (en) 2002-02-21
CN1447699A (zh) 2003-10-08
PL358809A1 (en) 2004-08-23
JP2004506024A (ja) 2004-02-26
CY1108898T1 (el) 2014-07-02
AU2001282059A1 (en) 2002-02-25
EP1309355A1 (de) 2003-05-14
DE50113975D1 (de) 2008-06-26
WO2002013872A1 (de) 2002-02-21
EP1309355B9 (de) 2009-04-08
CA2419423C (en) 2011-01-04

Similar Documents

Publication Publication Date Title
DK1309355T3 (da) Peptid og peptidmimetika-konjugater med integrin-inhibitor-egenskaber
MXPA03007358A (es) Transportadores que contienen porciones de arginina separadas.
RU94030480A (ru) Тиенопиримидиновые производные, способы их получения и фармацевтическая композиция
ATE345810T1 (de) Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend polypeptide
TW222642B (da)
MY116947A (en) Protease inhibitors
MY119155A (en) New peptide derivatives
ATE86964T1 (de) Malonsaeurederivate und ihre synthesemethoden.
CL2004001050A1 (es) Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul
MY133897A (en) N-(4-carb-amimidophenyl) glycineamide derivatives
WO2001005810A3 (de) CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6?
BR0308442A (pt) Composições farmacêuticas sólida e lìquida
US5231082A (en) Cyclic peptide with anti-metastasis activity
CA2315532A1 (en) Cyclopeptide derivatives with integrin inhibitor properties
JP2004506024A5 (da)
MXPA01011955A (es) Aminoacidos policiclicos, fusionados, como agentes farmaceuticos.
CY1108945T1 (el) Παραγωγα πεπτιδιων και πεπτιδομιμητικων ενωσεων με ιδιοτητες αναστολεα ενσωματινης ιι
TWI255813B (en) Compounds for use as alphavbeta3 receptor antagonists
ATE396177T1 (de) Neue kristalline formen eines faktor xa inhibitors
ATE178909T1 (de) Inhibitor peptid spezifisch für cathepsin-l
MX9205978A (es) Nuevas proteinas inhibidoras de trombina de garrapatas.
MY119431A (en) (het)arysulfonylureas having an amino function, their preparation and their use as herbicides and plant growth regulators
ECSP993211A (es) Inhibidores de proteasas vi
YU55798A (sh) Derivati n-(4-karbamimidofenilamino)-fenilglicinamida